Johnson & Johnson Management

Management criteria checks 2/4

Johnson & Johnson's CEO is Joaquin Duato, appointed in Jan 2022, has a tenure of 2.83 years. total yearly compensation is $28.40M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth €53.21M. The average tenure of the management team and the board of directors is 5 years and 4.9 years respectively.

Key information

Joaquin Duato

Chief executive officer

US$28.4m

Total compensation

CEO salary percentage	5.6%
CEO tenure	2.8yrs
CEO ownership	0.02%
Management average tenure	5yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joaquin Duato's remuneration changed compared to Johnson & Johnson's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 29 2024	n/a	n/a	US$15b
Jun 30 2024	n/a	n/a	US$16b
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$12b
Jul 02 2023	n/a	n/a	US$12b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensation vs Market: Joaquin's total compensation ($USD28.40M) is above average for companies of similar size in the German market ($USD4.77M).

Compensation vs Earnings: Joaquin's compensation has increased by more than 20% in the past year.

CEO

Joaquin Duato (61 yo)

2.8yrs

Tenure

US$28,397,240

Compensation

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Joaquin Duato	CEO & Chairman	2.8yrs	US$28.40m	0.015% € 53.2m
Joseph Wolk	Executive VP & CFO	6.3yrs	US$13.91m	0.0029% € 10.4m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8.6yrs	US$7.50m	0.0047% € 16.4m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.8yrs	US$11.00m	0.0064% € 22.6m
John Reed	Executive Vice President of Innovative Medicine	1.6yrs	US$20.65m	0.00061% € 2.1m
Robert Decker	Controller & Chief Accounting Officer	4.9yrs	no data	0.00082% € 2.9m
James Swanson	Executive VP & Chief Information Officer	5yrs	no data	0.00061% € 2.1m
Jessica Moore	Vice President of Investor Relations	3yrs	no data	no data
Dirk Brinckman	Chief Compliance Officer	no data	no data	no data
Elizabeth Forminard	Executive VP & Chief Legal Officer	2.1yrs	no data	0.00035% € 1.2m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	no data	no data
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	6.3yrs	no data	0.0034% € 12.1m

5.0yrs

Average Tenure

58yo

Average Age

Experienced Management: JNJ0's management team is considered experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Joaquin Duato	CEO & Chairman	2.8yrs	US$28.40m	0.015% € 53.2m
Anne Mulcahy	Independent Director	15.8yrs	US$410.00k	0.00034% € 1.2m
Hubert Joly	Independent Director	4.9yrs	US$320.00k	0.00021% € 738.5k
Marillyn Hewson	Lead Independent Director	5.6yrs	US$360.00k	0.00012% € 422.0k
Paula Johnson	Independent Director	1.8yrs	US$352.97k	0.000010% € 35.2k
Mark McClellan	Independent Director	11.1yrs	US$320.00k	0% € 0
Mary Beckerle	Independent Director	9.4yrs	US$355.00k	0% € 0
Darius Adamczyk	Independent Director	2.8yrs	US$340.00k	0.000040% € 140.7k
Jennifer Doudna	Independent Director	6.6yrs	US$320.00k	0% € 0
Eugene Woods	Independent Director	less than a year	US$89.15k	no data
Mark Weinberger	Independent Director	4.9yrs	US$340.00k	0% € 0
Nadja West	Independent Director	3.9yrs	US$340.00k	0% € 0

4.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: JNJ0's board of directors are considered experienced (4.9 years average tenure).

Johnson & Johnson Management

Management criteria checks 2/4

Key information

Recent management updates

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson Announces Executive Changes

Recent updates

Johnson & Johnson Announces Health Canada Authorizes CARVYKTI for Patients with Relapsed or Refractory Multiple Myeloma Who Receive One to Three Prior Lines of Therapy

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Johnson & Johnson Seeks U.S. FDA Approval of Spravato (Esketamine) as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age